Celldex Therapeutics Inc. (NASDAQ: CLDX) kicked off on November 20, 2023, at the price of $29.06, down -6.39% from the previous trading day. During the day, the shares moved up to $29.56 and dropped to $26.92 before settling in for the closing price of $29.09. Over the past 52 weeks, CLDX has traded in a range of $22.11-$48.40.
Elon Musk just Triggered a BOOM in These Stocks
Something strange is happening in the stock market…. This select group of stocks are going absolutely bananas. And it's all because of Elon Musk. Get your copy of "Top 5 Tech Stocks to Buy in 2024"
Click Here to Download the FREE Report.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -13.34%. While this was happening, its average annual earnings per share was recorded -18.99%. With a float of $53.67 million, this company’s outstanding shares have now reached $54.69 million.
Let’s determine the extent of company efficiency that accounts for 148 employees. In terms of profitability, gross margin is +40.60, operating margin of -4543.74, and the pretax margin is -4765.59.
Celldex Therapeutics Inc. (CLDX) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Celldex Therapeutics Inc. is 1.86%, while institutional ownership is 92.64%. The most recent insider transaction that took place on Dec 07, was worth 622,611. In this transaction EXECUTIVE VP & CSO of this company sold 16,860 shares at a rate of $36.93, taking the stock ownership to the 7,357 shares.
Celldex Therapeutics Inc. (CLDX) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 9/29/2023, the organization reported -$0.81 earnings per share (EPS), lower than consensus estimate (set at -$0.68) by -$0.13. This company achieved a net margin of -4765.59 while generating a return on equity of -30.13. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.82 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -18.99% per share during the next fiscal year.
Celldex Therapeutics Inc. (NASDAQ: CLDX) Trading Performance Indicators
Take a look at Celldex Therapeutics Inc.’s (CLDX) current performance indicators. Last quarter, stock had a quick ratio of 8.84. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 340.78.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.64, a number that is poised to hit -0.79 in the next quarter and is forecasted to reach -3.15 in one year’s time.
Technical Analysis of Celldex Therapeutics Inc. (CLDX)
Looking closely at Celldex Therapeutics Inc. (NASDAQ: CLDX), its last 5-days average volume was 1.19 million, which is a jump from its year-to-date volume of 0.57 million. As of the previous 9 days, the stock’s Stochastic %D was 46.99%. Additionally, its Average True Range was 1.91.
During the past 100 days, Celldex Therapeutics Inc.’s (CLDX) raw stochastic average was set at 31.57%, which indicates a significant decrease from 39.87% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 84.36% in the past 14 days, which was higher than the 48.16% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $26.35, while its 200-day Moving Average is $33.16. However, in the short run, Celldex Therapeutics Inc.’s stock first resistance to watch stands at $28.89. Second resistance stands at $30.54. The third major resistance level sits at $31.53. If the price goes on to break the first support level at $26.25, it is likely to go to the next support level at $25.26. Now, if the price goes above the second support level, the third support stands at $23.61.
Celldex Therapeutics Inc. (NASDAQ: CLDX) Key Stats
The company with the Market Capitalisation of 1.49 billion has total of 47,264K Shares Outstanding. Its annual sales at the moment are 2,360 K in contrast with the sum of -112,330 K annual income. Company’s last quarter sales were recorded 1,520 K and last quarter income was -38,260 K.